that medical patients. opportunity clinical This among Thank accomplished we've everyone. short need unmet very great you, product call our morning, global time a toward Judy, a exciting a you our dialysis and deal Rockwell for very time, In addresses today. We is good advancing joining a large for commercial Medical. Thank for our goals. see portfolio a and
long-term strengthen team sector, and for to we country year. have financing team now franchise. international launch with Triferic, Peru execution for to Let property the approval business for We a our IV our a in renal assembled, received top-notch developed the of me With start additional balance in-licensed We global support We strategic and accomplishments key sheet. completed pharmaceutical quarter this of a with fourth commercialization January guide some million first launch we $XX of experience Triferic management our efforts. support the and first marketing, Triferic XXXX. of to rights of plan the our assembled operations our the this intellectual general for in
our launching partners partners the XXXX, and Japan; of key second XXXX; NDA for geographies, of our for first of Triferic including the of formulation growing Triferic and of our quarter Dialysate Triferic, existing For in global the concentrates and milestones the and in new also continuing quarter XXXX; IV in the filing FDA formulation in Triferic development business. the profitability the through Europe identifying U.S., second improving include: XXX(b)X portfolio, second with
Let with various hemodialysis in Dialysis delivery potential to insufficient to therapy its current FDA-approved first and iron iron why the management the inflammation. to hemoglobin frankly, ESAs, improve iron has so we're and maintain to patients. anemia for marrow, IV reasons, in Triferic replacement me leads to due the The in compromising indicated patients. treatments system ability reticuloendothelial range. iron the only target start iron-deficient dialysis and excited of and patients anemia care in for is bone blood maintain loss patients, iron This hemodialysis and of of patient's thereby limitations. during hemodialysis hemoglobin standard become to of sequestration Triferic about deficiency including in
of effort blood that use significant reticuloendothelial primarily years, may many the evolved and system, iron in production is such by clinical proportion and products substantial in up are remain in IV ESA taken A in of red off-label generation. unavailable the liver These administered practice IV iron liver. cell iron reduce the are Over costs. to hemoglobin therefore, and the amounts for U.S. usage using in several has IV last clinics the an
iron has KDIGO or average skyrocketed levels hemodialysis above key recommended ferritin industry the patients result, levels by a and load in As including KDOQI. guidelines,
an of Studies have to action, reactions, increase here levels its improve through hypersensitivity nonalcoholic significantly patients ferritin and high to of linked guidelines. in risks in these hemodialysis infections, reduce been events liver introduced unique the patients, anemia In mechanism abroad. related has U.S. in fact, cardiovascular in significant in and than physiologic and the to U.S. potential ferritin the more patients including standard fatty XX% above have the have levels patients complications. adverse that hemodialysis the care for of the and Triferic, disease,
with Dialysate excited who we're constitutes unlike a liver iron sales of More hemoglobin of unique and at placebo why therefore, a later. the for million a of the sizable for has was opportunity launch safe nine it defined or ESAs, production it the blood Triferic. presents XX% anemia accounts the placebo is launch. the of other in more the the therapies, patients two year. and we without iron alone, the placebo nine In And uptake in the that iron we of XXX,XXX are XXXX, believe we in-center more in buildup with arm in potential for bypasses differentiator showed patients, and opportunity XX% the in no maintenance. binds hemodialysis hemodialysis cell over traditional products tissues. which or IV product a maintained offering discussed significant market more traditional months. the irons, patients Triferic liver the compared than Triferic compared unique the offers its products, iron I dialysis levels. transferrin, Furthermore, demonstrated $X months, about Triferic. that and as bone XX% application segment, the ESA there our patients and also Today, the is current replacement immediately billion. to than This portfolio. drug PRIME for So, This better to second And marrow large physiologic ESA reduction enthusiasm this XX% details for U.S. XX a earlier. among Triferic Triferic a with IV disease Triferic formulations: expect we they mechanism ferritin file And Dialysate our compared study, to importantly, And top patients upcoming in attractive use believe during less study the have to IV IV each the ESA more red gentle hypo-responder ESA-sparing U.S. to compared transports we reduction an us. arm, action, and with increase hyporesponsive and pharmacoeconomic And hemoglobin the findings approach for which And clinics. throughout receive These at clinical to In IV key is than level offer support quarter our so for outcomes because and very treatments renal U.S. study. iron organs of and IV end-stage are we on in a Triferic Triferic. adoption new Triferic PRIME
profile believe potential offer we in with Triferic to profile. a the and of addition standard existing proven Triferic so proposition. its to action, clinics for compared care pharmacoeconomic unique better the of has management, anemia safety strong mechanism a risk-benefit And offers hemodialysis And
We And about Triferic. formulations will result, and advance dialysis work multiple trialed as to think extremely that a unique on related data offer to to publication clinics continue clinics and have Triferic, alternatives to to Triferic a with patients. available economic harness health have that outcomes we're excited strategy we we
loop is system Each without formulation, of treatment central clinic then The with transported rooms have during Dialysate dialysis the for which the The solution through presentation XXXX. at launch Triferic. dialysis Triferic be clinics administered that ampoule at patients a presentation. packet liquid at quarter intend also clinic, Triferic, packet liquid patients. bicarbonate the we Triferic packet that Triferic central XX mixed the single to the powder loop can bicarbonate patients in enough initial a of a both all we to And second receive going bicarbonate are through can presentation both and that prevalent in system. Our U.S. is Dialysate to call liquid a provides presentations in We bedside, the of the powder the meaning through solution presentation consists water Dialysate powder a of of patient the
can we their through formulation, blood line be the call treatment. during patients Triferic, next which Our to directly administered IV dialysis
IV and year, and build of will an of of first Triferic Triferic believe launch Triferic launch on for the launch. are executives file our infrastructure second NDA to to promised for put our assembled we've at next upcoming for we'll groundwork our track will the work IV the quarter during approval with of been activities broad if Dialysate in we expect would experience, the building undertaking for we've Triferic, and We outstanding execute half an the team To the which approved. us rollout be be our an for We preparing XXXX, XXXX decision and instrumental potential of during these hard success, lay XXXX. industry
needed a we to also specifically activities last to and this spending the building launch opinion a team Triferic significant market Triferic Dialysate several commercial for targeted a already goods. that advisory educate and prepare of for with over boards and as the for the key We've months. conduct and leaders progressed process advantages. its including been accounts research, well fresh activities finished time of and plan launch. in and Our pricing key of amount have the are production medical There We're launch, engaging development franchise, execution Triferic, build around for field the is preparing awareness to commercial in several as
advantages beginning XXXX several next will to for Triferic that fully their the providers be that of years potential time due to practices. We course use has management the we've the commercial for medical the educate compelling to and product. the education Triferic standard us discussed, that some expect to it existing but focus changing will about over anemia clinics the process take care converting we of on of of expect become around Our the delivering
Dialysate launch the approach be at multipronged. specifically, Looking Triferic more will our
expect ramp and the make to to by sales, onboard, launch, XX have Triferic market. the Dialysate plan this launch have and broadly, to First, we we of medium-sized, to up medical organizations the to approximately the that program. approximately XX% end of centers a At the participated marketing, And we to dialysis small professionals U.S. year. plan people selected expect focus of trial independent we team Triferic dialysis target on more in that of
dialysis would Triferic the expect seeing conversion centers those time, For that for the cycle, are several first months. we
product XXXX. Triferic of the better Importantly, during the with and XXXX the in to our support be team we're experience launch customers building will gain IV valuable positioned and
several means special analyses Triferic under Triferic, new dosage Now, Dialysate design, IV the to formulation our the unique From protocol that and studies. our assessment and a FDA, the a and the separate form of trial FDA has clinical therefore, requires of developed IV which offer a let with and the the statistical routed standpoint, action endpoints same turn mechanism views it portfolio, me which next as a NDA. Triferic to FDA administration, benefits. in Triferic IV Triferic was additional as pre-agreed regulatory
the show bioequivalence to equivalence iron and rather FDA other be comparing than that As acceptable transferrin-bound part we IV Dialysate Triferic. were PK In Dialysate year, acceptable Triferic that running SPA, Triferic words, between Triferic. are In Triferic. for and Dialysate be parameters to and IV an of NDA agreed would if Triferic safety total of IV bioequivalence PK review our IV additional of the approach for efficacy Triferic demonstrated would by with iron able last completed trials, studies
FDA of was for in And anticipated in this NDA. the IV PDUFA NDA on that We the the presenting study of study in No offered from year, and March submit the were material for raised meeting. NDA date on data a potential during during received meeting, agreed the our of an issues FDA meeting the XXXX. XXth. to which the studies of filing approval our the during benefits the June the other equivalent pre-NDA FDA excited first submission We based the adequate Dallas be quarter plan potential in by equivalence from held will second Conference We're and to the additional about at Dialysis XXXX, the data with regarding we Annual with that this an half pre-NDA Triferic. and study feedback
for or eligible, payment XX protocols. are if Triferic view. while for Triferic approved centers And approval, XXXX, some the CMS adoption of more would U.S. make to dialysis as of offers Triferic believe others point to which clinics the convenience the to separate add-on IV a based another separate for patients. eligible months. administering We their on dialysis on clinics of IV adjustment, may anemia formulation, financial prefer new after recently that certain be option or a view announced And we for believe solution, likely it better from IV are remove therapies will dialysate January second, for a Triferic TDAPA, CMS to and First, the workflow beginning to subject help payments XXXX appealing transitional approved drug provides hurdles in for Triferic reimbursement period in X,
for Dialysate liquid dialysis since Japan, dialysis that than markets opportunity and Triferic utilize clinics is that international And must for predominantly in use Triferic monitors. Europe, Triferic. is mixed use, many Dialysate compatible we the believe monitors market dry And with bicarbonate Finally, not global such it's prior IV as these large larger to that China be of bicarbonate reason the this simply cartridges. with
reimbursement, the TDAPA by of time payment On final around topic deal experts clarity gain last of a to was November we've rule great consulting the and published that with spent CMS.
We be it Dialysate reimbursed launch we disclosed, by pricing even bundle for will product will providers, the previously the plan be of of Triferic market to achieve that margins the Triferic dialysis not we're meaning second finalizing a our determine attractive patients. reach to Triferic. Dialysate expect and we optimal within Medicare and for the product research broad quarter, for separately. making rate reimbursed pricing sales can base while the As commercial believe in affordable we bundle, within Accordingly, Dialysate
needs to potential clinicians it Triferic shift get require believe anemia most. hands and the the we management has and the importantly, to for and dialysis, patients More of it the who paradigm into
this a enthusiasm pharmacoeconomic managing to the and offers Triferic, that As population. KOLs advantages anemia the about great within leading paradigm and there we of of Triferic shift advantages the deal in potential begun is educate about clinical
a drug, Public Federal by Act X, as previously, approved for XXX a for for available qualify submitted mentioned a be dialysis outside and the plus as a be we drugs. eligible XXXX IV as service, must published injectable Triferic after under of to The ESRD therefore, Triferic, CMS. J-code TDAPA for and reimbursement CMS, Drug drugs believe application well to be by period or and IV renal will CMS Food November prospective system bundle criteria, According the can approval XXX as these new of January eligible or Health which renal we for all reimbursement review designated for meet ASP have a Act, Service that a that that in X%. dialysis Cosmetic was TDAPA final and be new by eligible includes believe Section to at to the the that payment commercially We are be of states Medicare subject XXXX approved CMS will of rule FDA for threshold Section months, product HCPCS TDAPA. by For XX
currently IV in after for the would TDAPA CMS regulatory are of payments, We Triferic us bundle. separate positioning with and into to it with X-year engaging window a optimally consultants go assist which likely
Turning United Biopharmaceuticals. to partner the Triferic working development States, China, of we've in made significant specifically our with the Wanbang progress, outside
one that other, We the are X which completed trial the in XXXX, CFDA early as have enrollment. coming has studies is by of which conducted expect clinical studies, and completed of PK in these being be will through likely months. part and the studies plan These was approved we that halfway initiated approximately dosing the
have CFDA. And these approval regulatory and meeting, by approval partner, of potential that late would from with outcome positive to with for Wanbang, XXXX. completion collaboration a Following later of to a meeting studies the with we sometime our a this pre-NDA our assuming in file we partner, expect equivalent expect year, the
IV the in believe process also While significant previously, our therapeutics, by certain China, agreement. I said a of And in opportunity we Triferic, to partner working since rights covers is to the license online largely Dialysate that has our generation. we are market adding Triferic is on agreement bicarbonate Triferic IV as and Triferic original new
We $XX approval patients. China for in and expect payments, IV opportunity, sales-based And milestone up the pathway later the that China. with price Triferic to provides also current Wanbang this of with XXX,XXX an regulatory the help will royalty. China hemodialysis double-digit transfer beginning year of of large and in the agreement a plus meeting attractive our million approval regulatory CFDA market with with for more Triferic clarify than represents
Moving international in to XXXX. we activities, Triferic approval Canada for on expect other regulatory to in our file for
realize we hemodialysis provides in Canada. expect to XX,XXX the our of in Latin there international us approval are for January and on a launch our that also excited Peru, We're of partner Triferic with first of economics an to approval this this opportunity agreement address distribution further patients sales We're and we Our of with QX looking the in population in in majority Dialysate year year, Triferic our next in Peru. of America in Chile. to than forward awaiting more expansion to received
partners unpartnered In identify to in XXX,XXX Japan. are priorities regions, hemodialysis are and Triferic IV Europe, international patients. for most Europe our forward, there notably Going than key more
In than in hemodialysis the patient discussions with a more XXX,XXX. for with Triferic. EMA license XXXX, intend would this reached study study attractive additional market parameters At do until During we Phase a III active a approval for linked could have provide pharmacoeconomic on data. agreement support primary which also we population an an study of The for Europe. Europe. include endpoint Japan to agreement a not we initiate to a regarding Japan, regulatory another is the in important with we're reached ESA-sparing, to time, partner
upfront us. We mix payable expect agreements, these milestone payments to of completed, would that and royalties include partnership if a payments,
of the $XX.X me Triferic, that turn Rockwell's for accounts substantially see While which supply improve opportunities is the industry, million including let and We're of portfolio. our Baxter much both opportunities DaVita, these today to the all therapeutic development say, at the lie give entree of business, the to us significant generated with companies relationships and of to U.S. directed of now concentrate key supplies exploring believe of around questions revenues for now ahead both concentrate were attention and also we now should the we I we and to QX opportunities XXXX. currently efficiencies We significant Last in -- economics amounts, further Calcitriol. concentrates to in regarding the new operational future players reach quarter, customers, internationally. the in well, achieve in of dialysis there business also a to number
is States, capacity share we assessment me market Let have at inventory consideration, best demand. that we reserving meaningful the manufacturing the review launching this with Simply that at of full see concluded And to in a a for And U.S. opportunity costs, Calcitriol interest the of sense. including that Calcitriol after in against a profit margin States completed margin not this in have Calcitriol approximately pricing, -- and revenues we as an in United careful accordingly, the $XXX,XXX. remaining the Rockwell time, put, do our generate time. not we're profit makes of United
financials. forward, our now to we market about developing our Angus will our conditions evaluate we're continue to in partner Angus? over Chinese Smith, in I turn that the CFO, with ongoing and market. call engaged review Going discussions Calcitriol launching will and to
